Precision medicine is reshaping healthcare, and the GigaAssay™ is leading the revolution. At EthicaMeds, we developed the GigaAssay™ to address one major flaw in traditional cancer treatment: lack of individualized data.
Unlike conventional genetic tests that detect known mutations, the GigaAssay™ assesses millions of genetic variations simultaneously. Powered by the Genomic Multiplex Library (GML), this platform evaluates how these mutations affect protein activity, gene regulation, and drug response in living cells.
This real-world, functional testing ensures that HER2+ breast cancer patients receive treatments proven to be effective based on their unique genetics. Instead of predicting outcomes theoretically, we deliver empirical, actionable results.
For breast cancer patients, this technology means faster, safer, and more effective treatments. For clinicians, it provides the clarity needed to prescribe with confidence.
The GigaAssay™ is not just innovation; it’s the future standard for precision oncology, and EthicaMeds is leading the way.
